EU and US could reach trade deal this weekend - Reuters
On Tuesday, Jefferies made an adjustment to the price target of agilon health Inc (NYSE:AGL), reducing it to $2.05 from the previous target of $4.75, while the firm maintained a Hold rating on the stock. The company, currently trading at $2.12 and down over 82% year-to-date, has seen its market value decline significantly amid challenging financial performance, including negative EBITDA of $321 million.
The change reflects the analyst's view that the company's management is implementing more significant measures to achieve profitability and positive cash flow by the year 2027. These measures include exiting certain partnerships and renegotiating payer contracts.
The analyst believes that it will take an additional twelve months to observe a material turnaround in the company's profitability. According to InvestingPro data, eight analysts have recently revised their earnings estimates downward, while the company's gross profit margin stands at a concerning -0.93%. Additionally, the analyst suggests that more time is needed to gain clarity on recent financial figures, which have been influenced by multiple years of significant prior year development (PYD) impacts. The revised price target of $2.05 is indicative of these considerations.
Agilon health's efforts to reach its financial goals have been closely monitored by market analysts. The company's strategy involves making significant changes to its business operations, which are expected to gradually contribute to its financial health. The analyst's commentary indicates a cautious outlook, acknowledging the steps being taken by management while also recognizing the need for more time to see substantial results.
The updated price target and rating by Jefferies serve as an indicator of the firm's expectations for agilon health's performance in the market. Investors often look to such adjustments as part of their considerations when making investment decisions. For a deeper understanding of agilon health's financial health and valuation, InvestingPro subscribers can access comprehensive analysis including 10 additional ProTips and detailed financial metrics in the Pro Research Report.
In summary, while Jefferies acknowledges the proactive measures being taken by agilon health's management, the firm anticipates that the benefits of these actions will become more apparent over a longer timeframe than previously expected. Based on InvestingPro Fair Value analysis, the stock appears undervalued at current levels, though the Hold rating remains in place, signaling that the analyst does not see significant movement in the stock's value in the immediate future.
In other recent news, Agilon Health has reported mixed results in its third-quarter financial report. The company saw a 28% increase in revenue year-over-year, reaching $1.45 billion, but fell short of the projected $1.47 billion. Additionally, Agilon Health experienced an adjusted EBITDA loss of $96 million, significantly missing both the analyst's estimate and the consensus estimate. In response to these results, TD Cowen and JMP Securities adjusted their outlook on Agilon Health, with TD Cowen reducing the company's price target and JMP Securities downgrading the stock rating.
In other developments, Agilon Health has updated indemnification agreements and relocated its headquarters to Westerville, Ohio. Despite financial challenges, the company reported a 37% year-over-year growth in Medicare Advantage membership and raised its full-year membership guidance. However, Agilon Health revised its full-year 2024 adjusted EBITDA guidance downward, indicating potential financial challenges ahead.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.